| (Values in U.S. Thousands) | Mar, 2023 | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 |
| Sales | 220 | 220 | 220 | 1,040 | 1,040 |
| Sales Growth | unch | unch | -78.85% | unch | unch |
| Net Income | -4,180 | 4,390 | -23,690 | -30,150 | -21,280 |
| Net Income Growth | -195.22% | +118.53% | +21.43% | -41.68% | +36.55% |
Humanigen Inc (HGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Humanigen, Inc. is a biopharmaceutical company. It focuses on advancing medicines for patients with neglected and rare diseases. The Company's product candidate principally consists of benznidazole, lenzilumab and ifabotuzumab. Humanigen Inc., formerly known as KaloBios Pharmaceuticals Inc., is based in Brisbane, United States.